Hedge fund advisory firm CR Intrinsic Investors will pay more than $600 million to settle the SEC’s allegation that it participated in an insider trading scheme involving a clinical trial for an Alzheimer’s drug being jointly developed by pharmaceutical companies Elan and Wyeth.
via SEC Announces Record $600 Million Insider Trading Settlement – Compliance Week
